A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer

Surgery

Volumn 140, Issue 6, 2006, Pages 960-967

  Kebebew, Electron ^a   Peng, Miao ^a   Reiff, Emily ^a   Treseler, Patrick ^b   Woeber, Kenneth A ^a   Clark, Orlo H ^a   Greenspan, Francis S ^a   Lindsay, Sheila ^a   Duh, Quan Yang ^a   Morita, Eugene ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RADIOACTIVE IODINE; ROSIGLITAZONE; THYROGLOBULIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLD; CONGESTIVE HEART FAILURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; LIVER TOXICITY; MALE; NEOPLASM; PELVIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; THYROID CANCER;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS;

EID: 33845561938     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.07.038     Document Type: Article

References (21)

1. Hundahl S.A., Fleming I.D., Fremgen A.M., and Menck H.R. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83 (1998) 2638-2648 [comments]
2. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84 (1999) 3877-3885
3. Goretzki P.E., Simon D., Frilling A., et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 80 (1993) 1009-1012
4. Cheung L., Messina M., Gill A., et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88 (2003) 354-357
5. Koeffler H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9 (2003) 1-9
6. Martelli M.L., Iuliano R., Le Pera I., et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87 (2002) 4728-4735
7. Ohta K., Endo T., Haraguchi K., Hershman J.M., and Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 2170-2177
8. Panigrahy D., Singer S., Shen L.Q., et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110 (2002) 923-932
9. Park J.W., Zarnegar R., Kanauchi H., et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15 (2005) 222-231
10. Karger S., Berger K., Eszlinger M., et al. Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid 15 (2005) 997-1003
11. Marques A.R., Espadinha C., Frias M.J., et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91 (2004) 732-738
12. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [published correction appears in Science 2000;289:1474]. Science 289 (2000) 1357-1360
13. Chung S.H., Onoda N., Ishikawa T., et al. Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93 (2002) 1358-1365
14. Sahin M., Allard B.L., Yates M., et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90 (2005) 463-468
15. Frohlich E., Machicao F., and Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12 (2005) 291-303
16. National Cancer Institute. Common toxicity criteria document. National Cancer Institute Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed January 13, 2005.
17. Grunwald F., Pakos E., Bender H., et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 39 (1998) 1555-1558
18. National Cancer Institute. Clinical trials. Available at: http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=2125112. Accessed February 27, 2006.
19. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., and Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89 (2003) 1409-1412
20. Philips J.C., Petite C., Willi J.P., Buchegger F., and Meier C.A. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 25 (2004) 1183-1186
21. Rumi M.A., Ishihara S., Kazumori H., Kadowaki Y., and Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr Med Chem Anticancer Agents 4 (2004) 465-477